|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Renewable-resource Thermoplastic Elastomers Based on Poly- lactide and Polymenthide显示文摘 | Carolyn L W Leslie E O Nathaniel A L | 2007 | Biomacromolecules2007，，8： | 1 |
| 2 | Entrepreneurs perceived chances for success显示文摘 | Cooper A C Carolyn Y W William C D | 1988 | Journal of Business Venturing1988，，3： | 1 |
| 3 | Instrument choice for environmental protection when technolgical in novation is endogenous显示文摘 | Parry Ian W H Pizer William A | 2003 | Journal of Regulatory Economics2003，45，： | 1 |
| 4 | Neuropilin‐1 and neuropilin‐2 expression in the adenoma–carcinoma sequence of colorectal cancer显示文摘 | Carolyn A Staton Ivan Koay Jessie M Wu Leslie Hoh Malcolm W R Reed Nicola J Brown | 2013 | Histopathology2013，，6： | 1 |
| 5 | Factors Influencing The Adoption of Multimedia Cable Technology显示文摘 | CAROLYN A L LEO W J | 1998 | Journalism and Mass Communication Quarterly1998，75，2： | 1 |
| 6 | Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice显示文摘 | Christopher L Bradley C G Francine S F Carolyn A W David E O Bernhard J H Zhifeng L Edward O Bruce E T Daniel R S | 2000 | Nature2000，407，： | 1 |
| 7 | Amino acid polymorphisms in Arabidopsis phytochrome B cause differential responses to light显示文摘 | Daniele L F Carolyn A W Jose R D | 2008 | PNAS2008，105，8： | 1 |
| 8 | Neuropilin‐1 and neuropilin‐2 expression in the adenoma–carcinoma sequence of colorectal cancer显示文摘 | Carolyn A Staton Ivan Koay Jessie M Wu Leslie Hoh Malcolm W R Reed Nicola J Brown | 2013 | Histopathology2013，，6： | 1 |
| 9 | Use of Double-stranded RNA Interference in Drosophila Cell Lines to Dissect Sigrlal Transduction Pathways显示文摘 | James C C Carolyn A W Nancy S L | 2000 | PNAs2000，97，： | 1 |
| 10 | Entrepreneurs Perceived chances for Success 显示文摘 | COOPER A C WILLIAM C W CAROLYN Y | 1988 | Journal of Business Venturing1988，，3： | 1 |
| 11 | Neuropilin‐1 and neuropilin‐2 expression in the adenoma–carcinoma sequence of colorectal cancer显示文摘 | Carolyn A Staton Ivan Koay Jessie M Wu Leslie Hoh Malcolm W R Reed Nicola J Brown | 2013 | Histopathology2013，，6： | 1 |
| 12 | Expression of Caenorhabditis elegans RNA-directed RNA polymerase in transgenic Drosophila melanogaster does not affect morphological development显示文摘 | Duan G W Robert B S Chris A H Carolyn A B Peter M W and Karl H J G | | 0，，： | 1 |
| 13 | When do the me- dium matter? Knowledge - building experiences and opportunities in decision- making teams 显示文摘 | J A BRADLEY W CAROLYN J K HOWARD | 2003 | Organizational Behavior and Human Decision Processes2003，，1： | 1 |
| 14 | Lipid and protein utilisation during early development of yellowtail kingfish Seriola lalandi显示文摘 | Hilton Z Carolyn W P Mary A S | 2008 | Marine Biology2008，154，： | 1 |
| 15 | Competing risks of death in younger and older postmenopausal breast cancer patients显示文摘AIM: To show a new paradigm of simultaneously testing whether breast cancer therapies impact other causes of death. METHODS: MA.14 allocated 667 postmenopausal women to 5 years of tamoxifen 20 mg/daily ± 2 years of octreotide 90 mg, given by depot intramuscular injections monthly. Event-free survival was the primary endpoint of MA.14; at median 7.9 years, the tamoxifen+octreotide and tamoxifen arms had similar event-free survival(P = 0.62). Overall survival was a secondary endpoint, and the two trial arms also had similar overall survival(P = 0.86). We used the median 9.8 years follow-up to examine by intention-to-treat, the multivariate time-to-breast cancer-specific(Br Ca) and other cause(OC) mortality with log-normal survival analysis adjusted by treatment and stratification factors. We tested whether baseline factors including Insulin-like growth factor 1(IGF1), IGF binding protein-3, C-peptide, body mass index, and 25-OH vitamin D were associated with(1) all cause mortality, and if so; and(2) cause-specific mortality. We also fit step-wise forward cause-specific adjusted models.RESULTS: The analyses were performed on 329 patients allocated tamoxifen and 329 allocated tamoxifen+octreotide. The median age of MA.14 patients was 60.1 years: 447(82%) < 70 years and 120(18%) ≥ 70 years. There were 170 deaths: 106(62.3%) BrC a; 55(32.4%) OC, of which 24 were other malignancies, 31 other causes of death; 9(5.3%) patients with unknown cause of death were excluded from competing risk assessments. BrC a and OC deaths were not significantly different by treatment arm(P = 0.40): tamoxifen patients experienced 50 BrC a and 32 OC deaths, while tamoxifen + octreotide patients experienced 56 Br Ca and 23 OC deaths. Proportionately more deaths(P = 0.004) were from BrC a for patients< 70 years, where 70% of deaths were due to Br Ca, compared to 54% for those ≥ 70 years of age. The proportion of deaths from OC increased with increasing body mass index(BMI)(P = 0.02). Higher pathologic T and N were associated with more BrC a deaths(P < 0.0001 and 0.002, respectively). The cumulative hazard plot for Br Ca and OC mortality indicated the concurrent accrual of both types of death throughout followup, that is the existence of competing risks of mortality. MA.14 therapy did not impact mortality(P = 0.77). Three baseline patient and tumor characteristics were differentially associated with cause of death: older patients experienced more OC(P = 0.01) mortality; patients with T1 tumors and hormone receptor positive tumors had less BrC a mortality(respectively, P = 0.01, P = 0.06). Additionally, step-wise cause-specific models indicated that patients with node negative disease experienced less BrC a mortality(P = 0.002); there was weak evidence that, lower C-peptide(P = 0.08) was associated with less BrC a mortality, while higher BMI(P = 0.01) was associated with worse OC mortality.CONCLUSION: We demonstrate here a new paradigm of simultaneous testing of therapeutics directed at multiple diseases for which postmenopausal women are concurrently at risk. Octreotide LAR did not significantly impact breast cancer or other cause mortality, although different baseline factors influenced type of death. | Judy-Anne W Chapman Kathleen I Pritchard Paul E Goss James N Ingle Hyman B Muss Susan F Dent Ted A Vandenberg Brian Findlay Karen A Gelmon Carolyn F Wilson Lois E Shepherd Michael N Pollak | 2014 | World Journal of Clinical Oncology2014，5，5： | 0 |
| 16 | Side effects and acceptability measures for thermal ablation as a treatment for cervical precancer in low-income and middle-income countries:a systematic review and meta-synthesis显示文摘Objective Understanding the side effects and acceptability of thermal ablation(TA)is necessary before large-scale application in screen-and treat programmes can be justified in low-income and middle-income countries(LMICs).Design Articles were selected for inclusion by two independent reviewers.Risk of bias was assessed using the Downs and Black’s criteria.Summary data were extracted,and authors contacted for data when necessary.Proportions of interest and 95%CIs were estimated using a random effects model.Subgroup analysis was performed based on place of treatment and timing of post-treatment follow-up.Heterogeneity was estimated using the I^(2).Eligibility criteria Studies that reported one or more side effects or patient acceptability measures after treatment of the cervix using TA in women living in LMICs who completed a cervical cancer screening test.Included articles were clinical trials or observational studies available in English and published before 18 December 2020.Information sources Ovid MEDLINE,EMBASE,CINAHL,CAB Global Health and WHO Global Index Medicus were searched for this systematic review and meta-synthesis.Results A total of 1590 abstracts were screened,84 full text papers reviewed and 15 papers selected for inclusion in the qualitative review,10 for meta-synthesis(N=2039).Significant heterogeneity was found in screening tests used to identify women eligible for TA and in methods to ascertain side effects.The most commonly reported side effect during treatment was pain(70%,95%CI 52%to 85%;I^(2)=98.01%)(8 studies;n=1454).No women discontinued treatment due to pain.At treatment follow-up,common side effects included vaginal discharge(72%,95%CI 18%to 100%;I^(2)=99.55%)(5 studies;n=771)and bleeding(38%,95%CI 15%to 64%;I^(2)=98.14%)(4 studies;n=856).Satisfaction with treatment was high in 99%(95%CI 98%to 100%;I^(2)=0.00%)of women(3 studies;n=679).Conclusions TA results in a number of common side effects,though acceptability remains high among women treated in LMICs.Standardised side effect and acceptability reporting are needed as TA becomes more readily available.PROSPERO registration number CRD42020197605. | Evelyne Marie Piret Beth A Payne Laurie W Smith Jessica Trawin Jackson Orem Gina Ogilvie Carolyn Nakisige | 2022 | Family Medicine and Community Health2022，10，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员